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Objective: Meropenem efficacy and tolerability was reported to measure up to 
imipenem/cilastatin, though some data reported that it may be more efficient in 
certain clinical and bacteriological settings. Our aim here is to demonstrate any 
possible difference between the two carbapenems in major septic clinical scenarios. 
Fever defervescence was selected as a clinical primary “broad” parameter to com-
pare the effectiveness of imipenem/cilastatin and meropenem on fever deferves-
cence in febrile septic patients.
Methods: A prospective multicenter, observational, comparative open label study. 
The study was conducted in three hospitals between February – September 2009 in 
Amman-Jordan. Data were collected for patients whom were started on imipenem/
cilastatin or meropenem; the study team did not contribute to the antibacterial 
selection for patients.
Results: Seventy patients were evaluated, thirty-two imipenem/cilastatin and thir-
ty-eight meropenem treated patients. Age mean was 60 and 57.6 years for Imipe-
nem/cilastatin and meropenem respectively. The APACHE II score was similar, mean 
14.4 for both study arms. There was no significant difference in rates of clinical 
diagnoses for both study arms; ventilator-associated pneumonia (VAP), urinary tract 
infection (UTI), intra-abdominal infections (IAI), blood stream infection (BSI) or for 
others sources. Additional anti-gram negative agents were administered in 10 and 
9 patients, added anti-MRSA agents in 11 and 12 patients, and antifungal agents 
in 3 and 1 patient in imipenem/cilastatin and meropenem treated patients respec-
tively. There was no significant difference between the mean temperatures (38,6 
0C for both), antimicrobial utilization days (8.33 versus 6.67), mean days for fever 
defervescence (3.31 versus 2.37, p = 0.36, 95% C.I. (-1.09 - 2.98) for imipenem/
cilastatin and meropenem treated patients respectively, mortality was the same.
Conclusion: There is no evidence to support the notion that there is clinical dif-
ference in fever defervescence between Imipenem/cilastatin and meropenem in 
this evaluated group.
This article is available from: 
www.iajaa.org
Introduction
Carbapenems are group of useful antibacterial agents that 
have broad coverage including aerobic (Gram-positive and 
Gram-negative) and anaerobic pathogens, they are reliable 
option for the initial empiric treatment of serious infections 
(1, 2). Imipenem/cilastatin has been in the Middle East for 
over two decades, a relatively new carbapenem to the area, 
meropenem was lately introduced. Its efficacy and tolerability 
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was reported to be similar to imipenem/cilastatin, though 
some data reported that it may be more efficient in certain 
clinical and bacteriological studies. (1, 3) Our aim is to demon-
strate any possible difference between the two carbapenems 
in major septic clinical scenarios. Fever defervescence was 
selected as a clinical primary “broad” outcome measure and 
mortality as a secondary outcome measure to assess their 
comparative efficacy. For the treating physician and patients, 
fever defervescence is a major parameter that demonstrates 




A prospective multicenter observational comparative open 
label study evaluating the difference in fever defervescence 
in adult febrile septic patients, when being treated with imi-
penem/cilastatin or meropenem, the study was approved by 
the internal review board of each hospital, study teams has 
no influence on the treating team for the selection of either 
antimicrobial. Patients’ selection took place by reviewing and 
following up cases which were treated with the concerned 
antibacterials. Sampling was done by recruiting all cases that 
were started on either carbapenem, the treating physicians 
start their patients on either carbapenem at their discretion. 
The administered doses were; imipenem/cilastatin 500 mg 
intravenous every 6 hours, or meropenem 1000 mg intrave-
nous every 8 hours. The study took place in three hospitals in 
Amman-Jordan with 610 beds, with 69 ICCU beds. The three 
hospitals host an array of patients including cancer patients, 
bone marrow transplant, solid organ transplants including 
kidney in all three hospitals, and one host in addition, liver 
transplants.
Diagnosis and recruitment of febrile septic 
patient
All patients with fever were selected defined as; Single rectal 
temperature of 38.2 C0 measured within twenty-four hours 
or two 38C0 spikes of fever at least two hours apart, and sys-
temic inflammatory response syndrome (SIRS) with suspicion 
or documentation of microbial cause. (4) SIRS criteria (38°C < 
Temperature < 36°C, Heart rate > 90 beats/min, Respiratory 
rate > 20 breaths/min, PaCO2 < 32 mm Hg, 12,000/mm3 < 
WBC < 4000/mm3, OR > 10% immature (band) forms). Pa-
tients’ temperature was measured rectally. When (rarely) tem-
perature was measured orally, a 0.5 C0 was added as a cor-
rection factor to account for rectal temperature. Normalized 
temperature is defined as any twenty-four hours without the 
above definition for fever. The acute physiologic and chronic 
health evaluation (APACHE II) score is used as a measure of 
patient clinical illness severity.
Eligibility
Eligible patients are all febrile septic patients who are ≥ 18 
years old. Both genders, meet definition of febrile sepsis, 
including patients with SSTI, CAP, HCAP, VAP (early and late), 
UTI, IAI, took carbapenem at least for three days, 500 mg i.v. 
every 6 hours for imipenem/cilastatin, or 1000 mg i.v. every 
8 hours for meropenem. Patients on previous antimicrobi-
als with continuous fever judged to have no response e.g. 
anti-MRSA agent, and a study antimicrobial was added for 
non-resolving fever.
Excluded patient are <18 years old, pregnant women or lac-
tating women, took the observed study antimicrobials for 
less than 3 days, ambiguity and repeated interruption of 
treatment and CNS infection. Blood culture growing MRSA, 
VRE or any organism resistant to either carbapenem, unless 
the patient was not improving on anti-MRSA agent and a 
study antimicrobial was added for non-resolving fever. Pa-
tients whom were on one study drug and switched to the 
other with fever defervescence in less than 48 hours. Pending 
mortality defined as death or anticipated death within 24 
hours of patients being on either antimicrobial, in addition 
to violation of the definition of septic patients.
Statistics
The aim of the study is to demonstrate whether there is a 
difference between imipenem/cilastatin and meropenem in 
how many days it took either study antimicrobial to defer-
vesce fever in treated patients. The comparison was done by 
testing the proportion difference between the defervescence 
days of both antimicrobials. The assumption is that there was 
no difference, otherwise it would be rejected, and existence 
of difference is declared. Proportions’ difference is assumed 
normality, its significance is tested by 95% confidence inter-
val (C.I. 95%) and P ≤ 0.05 was accepted as significance level. 
The number of patients needed to be studied assuming nor-
mal distribution following z statistics is ≥ 30 per study arm.
Outcome measures
The primary measure is the days’ difference in that imipenem/
cilastatin versus meropenem takes to normalize temperature 
for ≥ 48 continuous hours. The secondary outcome measure 
is mortality by discharge, including mortality after starting 
either study antimicrobial.
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Seventy patients were included, thirty-two in imipenem/cilas-
tatin and thirty-eight in meropenem treated patients. Age 
mean was 60 years for Imipenem/cilastatin and 57.6 years 
for meropenem. The APACHE II scores were similar (mean 
= 14.4). The clinical diagnoses were almost similar between 
the two groups for all diagnoses identified like VAP (early and 
late), UTI, IAI, BSI, undefined sepsis source or others diagnoses 
(Table 1). Additional gram-negative coverage in combination 
was utilized in 10 and 9 patients, added anti-MRSA agents in 
11 and 12 patients (though no MRSA was isolated later from 
both arms) and antifungal agents in 3 and 1 respectively in 
imipenem/cilastatin and meropenem, without significant sta-
tistical difference (Data not shown). There was no significant 
statistical difference in morbidities for both arms including 
diabetes, hematological malignancies, solid tumors, chronic 
liver disease and cerebrovascular accidents, but there were 
four cases of chronic renal failure and one renal transplant 
in meropenem treated patients. There was no significant dif-
ference between the mean temperature (38,6 0C for both) 
and antimicrobial utilization days (8.33 versus 6.67, difference 
= 1.56, 95% P = 0.33, C.I -1.61 – 4.73). The outcome mea-
sure; mean days for fever defervescence (3.31 versus 2.37, 
difference = 0.94 days, p = 0.36, 95% C.I -1.09 - 2.98) for 
imipenem/cilastatin and meropenem respectively. Mortality 
in both agents-treated patients was similar (Table 2).
Table 1.  Patients’ characteristics and demographic data for 
the comparative study of imipenem/cilastatin & 




Cilastatin N= 32 
(%)
Meropenem  
N = 38 (%)
Age in years 60.06 57.58
Gender Males 21(65.6) 28 (73.7)
 Females 11(34.4) 10 (26.3)
APACHE II Score
 Range





 ≤ 10 11 18
11 -20 12 9
≥ 21 7 11
Clinical Diagnosis
Early VAP 2 2
Late VAP 1 1
 UTI 5 7
 IAI 3 4
 BSI 3 4
 CAP 4 3
 HCAP 1 1
Sepsis (undefined) 7 10
 Others* 6 6
Morbidities






















Agents Added 11 12
Anti-Fungal 
Agents Added 3 1
Exclusion 4 4
Others*: Hypertension, coronary 









UTI: urinary tract infection
BSI: blood stream infection
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Discussion
Imipenem/cilastatin and meropenem are the only available 
carbapenems which are indicated in sever sepsis in our part 
of the world. (1) Ertapenem is also available, but severe sepsis 
and BSI are not among its labeled uses. However, it is licensed 
for the treatment of IAI that require or do not require surgery 
(5, 6, 7), diabetic foot infections, (8) HCAP and inpatient 
non-ICU HAP. (9, 10)
Earlier studies compared imipenem/cilastatin and meropen-
em for their in vitro susceptibility in gram-positive and gram-
negative isolate, (11, 12) clinical efficacy, tolerability, phar-
macodynamic/pharmacokinetic properties, dosing and cost 
effectiveness analysis. (13, 14, 15, 16) However, there were no 
studies found comparing fever defervescence as an important 
clinical indicator of efficacy. This study evaluates both car-
bapenems in febrile septic patients for fever defervescence, 
which was our main concern to demonstrate. As this pa-
rameter is perceived as an important efficacy parameter for 
physicians and patients. Both groups had a similar APACHE II 
score and clinical diagnoses underlying sepsis, including VAP, 
IAI, UTI, BSI and other unidentified sources.
In conclusion this study demonstrate that the difference in fe-
ver defervescence between imipenem/cilastatin and merope-
nem was not significant, P = 0.36, 95% C.I. (-1.09 - 2.98). 
Mortality during and at the end of therapy were similar in 
both groups. Although morbidities appear higher in merope-
nem, a renal transplant patient, four chronic renal failure pa-
tients as well as (others) undefined morbidities. A future study 
with larger study sample may adjust better for morbidity and 
microbiological match; it may be needed to amend for some 
confounders. 
Table 2.  Comparisons in imipenem/cilastatin and meropenem treated patients in temperature, antimicrobial utilization in 
days, mean days of fever defervescence and mortality in febrile septic patient. 
Parameter Imipenem/cilastatinN = 32
Meropenem
N = 38 Difference
 P value (95% C.I.) for 
the difference
Temperature* Mean and 
± S.D. 38.6 ± 0.53 38.6 ± 0.63 0.001 0.99 (- 0.28 - 28)
Antimicrobial Utilization 
Days Mean and ± S.D.  8.33 ± 8.6 6.76 ± 4.2 1.56 0.33 (-1.61 - 4.73)
Mean days to fever 
defervescence 3.31 2.37 0.94 0.36 (-1.09 - 2.98)
Mortality 6 6 0.0  ---
* Temperature maximum reading on the start of therapy
95%CI: Confidence interval at 95% level.
S.D: Standard deviation. N: number
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